
I share content on advanced endoscopy, clinical research and, sometimes, music. Posts in English and Spanish - Comparto contenidos sobre endoscopia avanzada, investigación clínica y, a veces, música. Publicaciones en inglés y español

Gastrointestinal Endoscopy Unit at @HospitalLaFe. Resarcher at @IISLaFe. Educational Twitter

I share content on advanced endoscopy, clinical research and, sometimes, music. Posts in English and Spanish - Comparto contenidos sobre endoscopia avanzada, investigación clínica y, a veces, música. Publicaciones en inglés y español

As some of you may remember, this year I’m sharing my “CV of failures.” Previous score: 3 failures – 0 successes. Three months later, the balance has improved… modestly: ❌ 4 rejections (+1 unsuccessful grant) ✅ 1 acceptance (+1 paper published) Still time for a comeback ⚽️

March feels like a good time to start my 2026 “CV of failures”: rejected grants, papers, ideas (doi.org/10.1038/nj7322-467a). It sounds like a joke, but it shows that every success hides a lot of effort. Current March score: Rejection 3 — Acceptance 0. - CV negativo: score trimestral

Our final review on CADx for colonic lesions is out! Not a typical narrative review, this is a practical guide for anyone questioning AI’s true value in colonoscopy, with clear insights on how to interpret CADx study results. Worth a read 👉 doi.org/10.1016/j.bpg.2025.1…

Optical diagnosis of a juvenile polyp: 👉reddish or red-brown color 👉smooth to slightly granular surface with frequent erosions and adherent mucus 👉low pit density with broad/irregular crypt openings and prominent but regular capillaries. NICE, JNET and Kudo do not apply!

Recently, a French study challenged the rectal location as a risk factor for SMIC contradicting findings, among others, from the classic Australian group study (Burgess, Gastroenterol2017). Now, see the Australian response in Gut. Is this a major takedown? gut.bmj.com/content/early/20…

Todo una oportunidad trabajar junto a @MarcoBus1967 👇🏻😊
📣 No podéis perderos el 4º caso del LIVE #SEED2025: cómo hacer un buen diagnóstico óptico y resección de una lesión en ciego de la mano de los expertos. El Dr. Jose Carlos Marín y el Dr Marco Bustamante nos enseñarán como plantear el diagnostico óptico y tratamiento de este tipo de lesiones @HospitalLaFe @SEEDendoscopia 📌 Jueves 20 de noviembre a las 09:00 horas en Auditorio 1 @PalcongresVLC ➕ congresoseed.es

New data in @endoscopyjrnl: 68.4% of postcolonoscopy colorectal cancers (PCCRC) may stem from missed lesions. Nearly 70% of PCCRCs could be preventable! Time to raise the bar for #Quality in #Colonoscopy 💪 @ESGE_news @aegastro doi:10.1055/a-2681-5642

En @LesArtsValencia, viendo dos óperas de #Marc-Antoine Charpentier. Que no sabéis quién es? Si que lo sabéis 👇 youtu.be/4LilPpv4uFI?si=qv4J…

This recent study in @GIE_Journal analyzed recurrence after pEMR. Only tubulovillous histology was associated with overall recurrence. But, 🧐 methodological issues. Other studies (Bobay GIE 2024; Tate GIE 2017) have identified size or HGD as risk factors sciencedirect.com/science/ar…

Polyp from a patient with sessile serrated polyposis. Detected with TXI (A), delineated with acetic acid (B), injected for further delineation/resection (C,D), and resected with piecemeal cold EMR (E,F). Follow the @ESGE_news EMR guidelines for better practice!💪

This trial offers the first high-quality data to address this important clinical question 👋 🇪🇸🇪🇸🇪🇸We now look forward to the TRIASSIC study results, from The Netherlands, to be presented at UEGW 2025. 🤨

And for your Hospital CEO .... ESD is cheaper 💰: he median total costs were €11,289.27 for TAMIS vs. €6,167.14 for ESD.

And here are the results! 💣: ➡️ Patients: 34 TAMIS - 39 ESD ➡️ Differences in RLR: −6.7% (90% CI, −14.2 to 0.8) in the ITT analysis 👉 non-inferiority ➡️ Secondary outcomes (ESD vs TAMIS): TSR 100% vs 88.9%; R0 83.7% vs 59.3%; ER0 93% vs 66.7%; ECRR 83.7% vs 59.3% 👉ESD better

What do these secondary outcomes mean?: 👉 ER0: complete resection with tumor-free margins regardless of the distance (you know that a 1 mm margin is arbitrary 👏) 👉 CRR: R0 + no high-risk features if adenocarcinoma 👉 ECRR: ER0 + no high-risk features if adenocarcinoma

1⃣Main outcome: rate of local recurrence (RLR) at 12 months pos-procedure. 2⃣Secondary outcomes: technical success rate (TSR); R0 resection rate (R0); expanded R0 (ER0); curative resection rate (CRR); expanded curative resection rate (ECRR).